Multicenter Phase II, Open-Label Trial of Intratumoral Tavokinogene Telseplasmid (TAVO, pIL-12) Plus Electroporation in Combination with Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment
Evaluate the efficacy of the combination of KEYTRUDA®, a registered trademark of Merck Sharp & Dohme Corp., and TAVO in advanced metastatic melanoma patients that are progressing on pembrolizumab or nivolumab.
Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma through Intratumoral pIL-12 Electroporation
Assess the anti-tumor efficacy (defined as the best overall response rate using RECIST v1.1) and safety of the combination of plasmid interleukin-12 electroporation and pembrolizumab in patients with low tumor-infiltrating lymphocyte (TIL) melanoma†.
†This is a collaboration with University of California, San Francisco
OMS-140 Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients with Triple Negative Breast Cancer (TNBC)
Evaluate the potential of intratumoral treatment with pIL-12 delivered via electroporation to promote a pro-inflammatory molecular and histological signature in patients with triple negative breast cancer.